Article Text

PDF
Perindopril plus indapamide reduced death and major macrovascular and microvascular events in type 2 diabetes

Statistics from Altmetric.com

A Patel

Dr A Patel, University of Sydney, Sydney, New South Wales, Australia; apatel@george.org.au

STUDY DESIGN

Design:

randomised controlled trial (Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation [ADVANCE]).

Allocation:

concealed.*

Blinding:

blinded (outcome assessors, {patients, clinicians, data collectors, data analysts, and manuscript writers}).*†

STUDY QUESTION

Setting:

215 centres in 20 countries in Asia, Australasia, Europe, and North America.

Patients:

11 140 patients ⩾55 years of age (mean age 66 y, 57% men) who were diagnosed with type 2 diabetes mellitus at ⩾30 years of age and had ⩾1 of the following: history of major cardiovascular disease or risk factor for cardiovascular disease (ie, history of major microvascular disease, current cigarette smoking, total cholesterol >6.0 mmol/l, high-density lipoprotein cholesterol <1.0 mmol/l, urinary albumin-creatinine ratio 30–300 μg/mg, diagnosis of type 2 diabetes ⩾10 years previously, or age ⩾65 y). Exclusion criteria included definite indication for an angiotensin-converting enzyme inhibitor other …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.